{"entity":{"id":"sx-682","kind":"drug","name":"SX-682","aka":[],"tldr":"SX-682 is an experimental tablet from Syntrix Pharmaceuticals that blocks the CXCR1 and CXCR2 receptors on immune-suppressing cells. It is in phase 2 trials, alone or with other medicines, in prostate cancer, lung cancer and other cancers.","summary":"SX-682 is Syntrix Pharmaceuticals' CXCR1/2 inhibitor. Registered trials in OnCo include NCT06228053, a Syntrix-sponsored phase 2 trial with enzalutamide in metastatic castration-resistant prostate cancer; NCT05570825 and NCT07322341, University of Washington trials with pembrolizumab and with atezolizumab in non-small cell lung cancer; and NCT06149481, a National Cancer Institute trial combining it with a vaccine, retifanlimab and N-803 in metastatic colorectal cancer. NCI SBIR awards to Syntrix in 2026 fund studies in myelodysplastic syndromes and melanoma.","status":"phase-2","asOf":"2026-11-04","links":[{"label":"Syntrix Pharmaceuticals: SX-682","url":"https://syntrixbio.com/pages/immuno-oncology/"},{"label":"ClinicalTrials.gov: trials of SX-682","url":"https://clinicaltrials.gov/search?intr=SX-682"}],"tags":["pipeline"],"related":[],"cancers":["prostate","nsclc","colon-cancer","rectal-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["syntrix-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06228053","nct05570825","nct07322341","nct06149481"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"SX-682","modality":"Oral small-molecule inhibitor","mechanism":"A dual inhibitor of the chemokine receptors CXCR1 and CXCR2, which Syntrix Pharmaceuticals describes as inactivating the myeloid-derived suppressor cells and neutrophils that shield tumours from T cells and natural killer cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/sx-682/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"company":[{"id":"syntrix-pharmaceuticals","kind":"company","name":"Syntrix Pharmaceuticals","route":"/companies/syntrix-pharmaceuticals/"}],"trial":[{"id":"nct06149481","kind":"trial","name":"Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Can","route":"/trials/nct06149481/"},{"id":"nct06228053","kind":"trial","name":"Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer","route":"/trials/nct06228053/"},{"id":"nct07322341","kind":"trial","name":"SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer","route":"/trials/nct07322341/"},{"id":"nct05570825","kind":"trial","name":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","route":"/trials/nct05570825/"}]}}